The Effect of the COVID-19 Pandemic on Primary Bladder Cancer Presentations
1 other identifier
observational
183
1 country
1
Brief Summary
In this study, investigators aim to reveal how the COVID-19 pandemic process affects primary bladder cancer presentations, tumor stages and degrees, the time elapsed between diagnosis and intervention, tumor recurrence and progression, which are oncological results.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jul 2021
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 23, 2021
CompletedFirst Posted
Study publicly available on registry
May 25, 2021
CompletedStudy Start
First participant enrolled
July 1, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
August 15, 2021
CompletedOctober 6, 2021
September 1, 2021
1 month
May 23, 2021
September 29, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Rate of tumor stages
Rate of tumor stages in patients who diagnosed with bladder cancer
2 months
Study Arms (2)
COVID-19 Bladder Cancer
Patients diagnosed with primary bladder cancer in the COVID-19 period
PreCOVID-19 Bladder Cancer
Patients diagnosed with primary bladder cancer in the preCOVID-19 period
Interventions
Patients diagnosed with primary bladder cancer by transurethral resection in the urology clinic during and before the COVID-19 pandemic will be retrospectively evaluated and compared.
Eligibility Criteria
Patients diagnosed with primary bladder cancer by transurethral resection in the urology clinic.
You may qualify if:
- Primary bladder cancer
You may not qualify if:
- Previous history of urinary tract tumor
- Chronic kidney disease
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Ankara Training and Research Hospital
Ankara, Altindag, 06230, Turkey (Türkiye)
Related Publications (3)
Heldwein FL, Loeb S, Wroclawski ML, Sridhar AN, Carneiro A, Lima FS, Teoh JY. A Systematic Review on Guidelines and Recommendations for Urology Standard of Care During the COVID-19 Pandemic. Eur Urol Focus. 2020 Sep 15;6(5):1070-1085. doi: 10.1016/j.euf.2020.05.020. Epub 2020 Jun 5.
PMID: 32532703BACKGROUNDEsperto F, Pang KH, Albisinni S, Papalia R, Scarpa RM. Bladder Cancer at the time of COVID-19 Outbreak. Int Braz J Urol. 2020 Jul;46(suppl.1):62-68. doi: 10.1590/S1677-5538.IBJU.2020.S107.
PMID: 32549074BACKGROUNDWallis CJD, Novara G, Marandino L, Bex A, Kamat AM, Karnes RJ, Morgan TM, Mottet N, Gillessen S, Bossi A, Roupret M, Powles T, Necchi A, Catto JWF, Klaassen Z. Risks from Deferring Treatment for Genitourinary Cancers: A Collaborative Review to Aid Triage and Management During the COVID-19 Pandemic. Eur Urol. 2020 Jul;78(1):29-42. doi: 10.1016/j.eururo.2020.04.063. Epub 2020 May 3.
PMID: 32414626BACKGROUND
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Ali Kaan Yildiz
Ankara Training and Resarch Hospital
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
May 23, 2021
First Posted
May 25, 2021
Study Start
July 1, 2021
Primary Completion
August 1, 2021
Study Completion
August 15, 2021
Last Updated
October 6, 2021
Record last verified: 2021-09
Data Sharing
- IPD Sharing
- Will not share